Could investing in the pharmaceutical giant pay off over the next five years? I think so, and here is why. AbbVie has a ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...

Psoriatic arthritis is an autoimmune condition that causes joint inflammation, skin symptoms, and pain. People searching for psoriatic arthritis prescriptions are often looking for detailed ...

Billy is a Senior Features Author for Collider. Having written over 300 articles in just over a year, Billy regularly covers the biggest TV shows and films releasing while also analysing some of the ...

And by the end of the decade, J&J is expecting double-digit annual growth, said CEO Joaquin Duato on an analysts' call.

AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income. The JEPQ ETF employs a covered-call ...

CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total ...

AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV’s valuation remains attractive; a 14.4x FY 2027 multiple is ...